ARMS tumors express a higher level of the fusion products, PAX3/FKHR and PAX7/FKHR, accompanied by a much higher transcriptional activation than the wild type PAX proteins. This evidence concerns the gene PAX7 and alveolar rhabdomyosarcoma.